Core Viewpoint - XuanZhu Biotech-B (02575) has seen a significant stock price increase, rising over 415% from its IPO price of 11.6 HKD to a peak of 59.85 HKD, reflecting strong market interest following the presentation of clinical trial results [1] Company Developments - XuanZhu Biotech announced the presentation of clinical III phase results for the BRIGHT-3 study at the 2025 European Society for Medical Oncology (ESMO) conference, focusing on the combination of palbociclib with letrozole or anastrozole for HR+/HER2- advanced breast cancer [1] - The BRIGHT-3 study is a randomized, double-blind clinical trial conducted at 58 centers in China, aimed at evaluating the efficacy and safety of palbociclib combined with aromatase inhibitors in first-line treatment for HR+/HER2- advanced breast cancer [1] - Based on the mid-term data from the BRIGHT-3 study, the National Medical Products Administration of China accepted the new drug application for palbociclib in combination with aromatase inhibitors for HR+/HER2- advanced breast cancer on May 14 [1]
轩竹生物-B涨幅扩大至30% 吡洛西利治疗乳腺癌临床III期研究数据于ESMO公布